Interleukin-17 inhibition in psoriatic arthritis. (Q52836676)

8 May 2018

title

Interleukin-17 inhibition in psoriatic arthritis. (English)

1 reference

8 May 2018

1

Philip Helliwell

0 references

Laura C. Coates

series ordinal

2

object named as

Laura Coates

0 references

language of work or name

English

0 references

publication date

26 June 2015

1 reference

8 May 2018

published in

The Lancet

1 reference

8 May 2018

volume

386

1 reference

8 May 2018

issue

9999

1 reference

8 May 2018

page(s)

1114-1116

1 reference

8 May 2018

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2961170-9

1 reference

7 January 2021

Psoriatic arthritis. Follow-up study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2961170-9

7 January 2021

Treatment recommendations for psoriatic arthritis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2961170-9

7 January 2021

Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2961170-9

7 January 2021

Secukinumab in plaque psoriasis--results of two phase 3 trials.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2961170-9

7 January 2021

Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2961170-9

7 January 2021

Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2961170-9

7 January 2021

Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phas

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2961170-9

7 January 2021

10.1016/S0140-6736(15)61170-9

Identifiers

DOI

1 reference

8 May 2018

PubMed ID

26135705

1 reference

8 May 2018